PL373490A1 - Use of beta-adrenoceptor agonists for the treatment of neurodegenerative diseases - Google Patents
Use of beta-adrenoceptor agonists for the treatment of neurodegenerative diseasesInfo
- Publication number
- PL373490A1 PL373490A1 PL02373490A PL37349002A PL373490A1 PL 373490 A1 PL373490 A1 PL 373490A1 PL 02373490 A PL02373490 A PL 02373490A PL 37349002 A PL37349002 A PL 37349002A PL 373490 A1 PL373490 A1 PL 373490A1
- Authority
- PL
- Poland
- Prior art keywords
- beta
- treatment
- neurodegenerative diseases
- adrenoceptor agonists
- adrenoceptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Addiction (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10142175A DE10142175A1 (en) | 2001-10-09 | 2001-08-29 | Use of beta-adrenoceptor agonists, e.g. reproterol, salmeterol or terbutaline, for restoring and/or maintaining function of damaged nerve cells, e.g. for treatment of neurodegenerative diseases |
DE10142178A DE10142178A1 (en) | 2001-08-29 | 2001-08-29 | Use of beta-adrenoceptor agonists, e.g. reproterol, salmeterol or terbutaline, for restoring and/or maintaining function of damaged nerve cells, e.g. for treatment of neurodegenerative diseases |
DE10142176A DE10142176A1 (en) | 2001-08-29 | 2001-08-29 | Use of beta-adrenoceptor agonists, e.g. reproterol, salmeterol or terbutaline, for restoring and/or maintaining function of damaged nerve cells, e.g. for treatment of neurodegenerative diseases |
DE10149611A DE10149611A1 (en) | 2001-08-29 | 2001-10-09 | Use of beta-adrenoceptor agonists, e.g. reproterol, salmeterol or terbutaline, for restoring and/or maintaining function of damaged nerve cells, e.g. for treatment of neurodegenerative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
PL373490A1 true PL373490A1 (en) | 2005-09-05 |
Family
ID=27438007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL02373490A PL373490A1 (en) | 2001-08-29 | 2002-08-22 | Use of beta-adrenoceptor agonists for the treatment of neurodegenerative diseases |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1420772A2 (en) |
JP (1) | JP2005505548A (en) |
AU (1) | AU2002333510A1 (en) |
PL (1) | PL373490A1 (en) |
WO (1) | WO2003020257A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1754474A1 (en) * | 2005-02-02 | 2007-02-21 | Eucro European Contract Research GmbH & Co. KG | Use of S-Clenbuterol |
GB0519274D0 (en) * | 2005-09-21 | 2005-11-02 | Arakis Ltd | The treatment of neurodegenerative diseases |
AU2007226134A1 (en) * | 2006-03-16 | 2007-09-20 | Mor Research Applications Ltd. | Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels |
CN101915841B (en) * | 2010-07-26 | 2013-01-02 | 河南省科学院生物研究所有限责任公司 | Ternary detection test bar of beta-stimulants albuterol, clenobuterol hydrochloride and ractopamine and preparation method thereof |
US9265735B2 (en) | 2010-11-30 | 2016-02-23 | New York University | Methods for screening to identify therapeutic agents for Alzheimer's disease and use thereof |
US20140249180A1 (en) * | 2011-10-03 | 2014-09-04 | National Center For Geriatrics And Gerontology | Tau aggregation inhibitor |
EP2962687B1 (en) | 2013-04-02 | 2019-06-05 | The Doshisha | Tau aggregation inhibitor |
CN115531368A (en) * | 2021-06-14 | 2022-12-30 | 谭文 | Application of R-carbamate-beta-phenylethanolamine compounds in treatment of learning and memory deficiency and neurodegenerative diseases |
CN116236467B (en) * | 2023-02-07 | 2023-10-27 | 中国人民解放军总医院 | New application of simatron or derivative thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5334618A (en) * | 1991-04-04 | 1994-08-02 | The Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
EP0392059B1 (en) | 1989-04-14 | 1993-09-15 | Merz & Co. GmbH & Co. | Use of adamantane derivatives in the prevention and treatment of cerebral ischemia |
US5281607B1 (en) * | 1992-10-08 | 1998-05-19 | Univ New York | Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases |
US5958919A (en) * | 1996-09-20 | 1999-09-28 | Washington University | Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration |
AU1731101A (en) * | 1999-12-07 | 2001-06-18 | Rohto Pharmaceutical Co., Ltd. | Ophthalmic compositions |
CA2411666A1 (en) * | 2000-06-01 | 2001-12-06 | Children's Medical Center Corporation | Methods and compositions for producing a neurosalutary effect in a subject |
US7135497B1 (en) * | 2000-07-07 | 2006-11-14 | New York Medical College | Treating neural conditions resulting from spinal cord contusions and other causes |
-
2002
- 2002-08-22 PL PL02373490A patent/PL373490A1/en not_active Application Discontinuation
- 2002-08-22 EP EP02797607A patent/EP1420772A2/en not_active Withdrawn
- 2002-08-22 JP JP2003524566A patent/JP2005505548A/en active Pending
- 2002-08-22 WO PCT/EP2002/009369 patent/WO2003020257A2/en active Application Filing
- 2002-08-22 AU AU2002333510A patent/AU2002333510A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2002333510A1 (en) | 2003-03-18 |
JP2005505548A (en) | 2005-02-24 |
WO2003020257A3 (en) | 2004-01-08 |
WO2003020257A2 (en) | 2003-03-13 |
EP1420772A2 (en) | 2004-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL159344A0 (en) | Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease | |
ZA200401004B (en) | Combination for the treatment of inflammatory disorders | |
IL160389A0 (en) | Use of flibanserin for the treatment of sexual disorders | |
IL150742A0 (en) | Pyridopyrimidinone derivatives for the treatment of neurodegenerative disease | |
HUP0400314A3 (en) | Pharmaceutical combinations for the treatment of cancer | |
IL161267A0 (en) | Combinations for the treatment of immunoinflammatory disorders | |
HUP0400024A3 (en) | Combination for treatment of neoplastic diseases | |
IL157145A0 (en) | Use of dc23 antagonists for the treatment of neoplastic disorders | |
PL373490A1 (en) | Use of beta-adrenoceptor agonists for the treatment of neurodegenerative diseases | |
GB0119370D0 (en) | Therapeutic agent | |
AU2002344959A1 (en) | Use of fasl for the treatment of neurodegenerative diseases | |
GB0123991D0 (en) | New therapeutic use | |
GB0128122D0 (en) | Therapeutic use | |
GB0222282D0 (en) | Therapeutic device for the treatment of symptons caused by diseases | |
AU2002365654A8 (en) | Treatment of diseases via the skin | |
GB0203173D0 (en) | The treatment of neurodegenerative disease | |
GB0107114D0 (en) | New therapeutic use | |
GB0112491D0 (en) | New therapeutic use | |
GB0128304D0 (en) | New therapeutic use | |
GB0110584D0 (en) | New therapeutic use | |
GB0128300D0 (en) | New therapeutic use | |
GB0119462D0 (en) | New therapeutic use | |
GB0110585D0 (en) | New therapeutic use | |
GB0128123D0 (en) | Therapeutic use | |
GB0128089D0 (en) | Therapeutic use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |